U
ENTA icon

UBS’s Enanta Pharmaceuticals ENTA Stock Holding History

UBS’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-50
Closed -$1.99K – 10452
2014
Q2 		$2K Buy
50
+42
+525% +$1.6K ﹤0.01% 10018
2014
Q1 		$0 Sell
8
-276
-97% -$10K ﹤0.01% 10517
2013
Q4 		$8K Sell
284
-3,374
-92% -$81.8K ﹤0.01% 9179
2013
Q3 		$84K Buy
3,658
+2,542
+228% +$48.6K ﹤0.01% 6217
2013
Q2 		$20K Buy
+1,116
New +$21.8K ﹤0.01% 7881

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

UBS's ENTA Position: Q3 2014 in Review

UBS sold out of Enanta Pharmaceuticals (ENTA) in Q3 2014, closing a stake of 50 shares — an estimated $1.99K sold.

UBS first reported a position in ENTA in Q2 2013 and held it in 5 quarters. The position peaked at $84K in Q3 2013. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2014.

  • UBS reported no remaining Enanta Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • UBS sold 50 Enanta Pharmaceuticals shares in Q3 2014, an estimated $1.99K.
  • UBS first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • UBS's Enanta Pharmaceuticals position peaked at $84K in Q3 2013.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.